SanaCurrents on Equillium’s (EQ) potential entrant to treat Lupus nephritis (LN)

By |2023-02-21T08:41:03-05:00February 19th, 2023|Tags: |

Equillium, Inc. (NASDAQ:EQ) Probability Sentiment SUMMARY Six-year-old Equillium, Inc.’s (NASDAQ:EQ) lead drug, itolizumab, is in [...]